Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Solid Tumors 2Thrombocythemia, Essential 1Rhabdoid Tumor 1Polycythemia Vera 1Leukemia, Myeloid, Acute 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 6Filgrastim 5Etoposide 5fludarabine 4Temozolomide 4Granulocyte Colony-Stimulating Factor 4Carboplatin 4Thiotepa 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Automobiles 3tazemetostat 2sargramostim 2ribociclib 2fludarabine phosphate 2Vorinostat 2Vincristine 2Topotecan 2Sirolimus 2Mesna 2Busulfan 2veliparib 1trametinib 1thymoglobulin 1sonidegib 1selinexor 1reolysin 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rhabdoid Tumor × RG7388 × Clear all
NCT05952687 2024-03-27

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

St. Jude Children's Research Hospital

Phase 1 Withdrawn
CNS

Central Nervous System Neoplasms, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡